Trial Outcomes & Findings for Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI) (NCT NCT01450800)
NCT ID: NCT01450800
Last Updated: 2017-02-13
Results Overview
The primary outcome was treatment for UTI within the first 3 weeks after surgery. Treatment for UTI was defined to include any treatment received for clinically suspected or culture-proven urinary tract infection within 3 weeks of surgery. Clinically suspected treatment was defined to include treatment given empirically upon development of urinary symptoms or prescribed based on urine test results. Culture-proven UTI was defined as a urine culture with greater than 100,000 colony-forming units of a single organism.
COMPLETED
PHASE4
163 participants
three weeks post-operative
2017-02-13
Participant Flow
Patients who received postoperative transurethral catheterization after surgery for pelvic organ prolapse, urinary incontinence, or both by the Division of Urogynecology at Duke University Medical Center from 8/2011 through 2/2013 were identified, recruited and enrolled after providing written informed consent at a routine pre-operative visit.
Randomization occurred within a few hours after surgery. Participants were excluded prior to randomization if they sustained intraoperative injury to the urinary tract requiring prolonged catheterization, or if they passed an immediate void trial on day of surgery (as these participants did not receive additional postoperative catheterization).
Participant milestones
| Measure |
Nitrofurantoin
Randomized to nitrofurantoin 100mg daily for each day of catheterization for up to 7 days
|
Placebo
Randomized to placebo 1 tablet daily for each day of catheterization for up to 7 days
|
|---|---|---|
|
Overall Study
STARTED
|
82
|
81
|
|
Overall Study
COMPLETED
|
81
|
78
|
|
Overall Study
NOT COMPLETED
|
1
|
3
|
Reasons for withdrawal
| Measure |
Nitrofurantoin
Randomized to nitrofurantoin 100mg daily for each day of catheterization for up to 7 days
|
Placebo
Randomized to placebo 1 tablet daily for each day of catheterization for up to 7 days
|
|---|---|---|
|
Overall Study
Protocol Violation
|
1
|
3
|
Baseline Characteristics
Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)
Baseline characteristics by cohort
| Measure |
Nitrofurantoin
n=82 Participants
Participants randomized to receive antibiotics instructed to take nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
|
Placebo
n=81 Participants
Participants randomized to receive placebo instructed to take placebo 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
|
Total
n=163 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
58 Participants
n=5 Participants
|
55 Participants
n=7 Participants
|
113 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
24 Participants
n=5 Participants
|
26 Participants
n=7 Participants
|
50 Participants
n=5 Participants
|
|
Age, Continuous
|
57 years
STANDARD_DEVIATION 13 • n=5 Participants
|
57 years
STANDARD_DEVIATION 13 • n=7 Participants
|
57 years
STANDARD_DEVIATION 13 • n=5 Participants
|
|
Gender
Female
|
82 Participants
n=5 Participants
|
81 Participants
n=7 Participants
|
163 Participants
n=5 Participants
|
|
Gender
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
82 participants
n=5 Participants
|
81 participants
n=7 Participants
|
163 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: three weeks post-operativePopulation: Intent-to-treat analysis
The primary outcome was treatment for UTI within the first 3 weeks after surgery. Treatment for UTI was defined to include any treatment received for clinically suspected or culture-proven urinary tract infection within 3 weeks of surgery. Clinically suspected treatment was defined to include treatment given empirically upon development of urinary symptoms or prescribed based on urine test results. Culture-proven UTI was defined as a urine culture with greater than 100,000 colony-forming units of a single organism.
Outcome measures
| Measure |
Nitrofurantoin
n=81 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
n=78 Participants
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Urinary Tract Infections
|
18 participants
|
10 participants
|
SECONDARY outcome
Timeframe: 3 weeks following surgeryPopulation: Used entire study population to determine risk factors for UTI
We examined risk of UTI as related to vaginal estrogen therapy
Outcome measures
| Measure |
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Other Risk Factors for UTI
participants with no UTI
|
131 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI not on vaginal estrogen
|
24 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI on vaginal estrogen
|
4 participants
|
—
|
SECONDARY outcome
Timeframe: 3 weeks following surgeryPopulation: Used entire study population to determine risk factors for UTI
We examined risk of UTI as related to history of recurrent UTIs
Outcome measures
| Measure |
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Other Risk Factors for UTI
participants with no UTI
|
131 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with recurrent UTI
|
4 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with no recurrent UTI
|
24 participants
|
—
|
SECONDARY outcome
Timeframe: 3 weeks following surgeryPopulation: Used entire study population to determine risk factors for UTI
We examined risk of UTI as related to preoperative UTI treatment
Outcome measures
| Measure |
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Other Risk Factors for UTI
participants without UTI
|
131 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with preoperative UTI
|
3 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with no preoperative UTI
|
25 participants
|
—
|
SECONDARY outcome
Timeframe: 3 weeks following surgeryPopulation: Used entire study population to determine risk factors for UTI
We examined risk of UTI as related to Creatinine Clearance
Outcome measures
| Measure |
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Other Risk Factors for UTI
Participants with UTI
|
115 mL/min
Standard Deviation 37
|
—
|
|
Other Risk Factors for UTI
Participants without UTI
|
101 mL/min
Standard Deviation 30
|
—
|
SECONDARY outcome
Timeframe: 3 weeks following surgeryPopulation: Used entire study population to determine risk factors for UTI
We examined risk of UTI as related to sling as part of surgery
Outcome measures
| Measure |
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Other Risk Factors for UTI
participants with no UTI
|
131 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with sling
|
16 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with no sling
|
12 participants
|
—
|
SECONDARY outcome
Timeframe: 3 weeks following surgeryPopulation: Used entire study population to determine risk factors for UTI
We examined risk of UTI as related to total postoperative catheter days
Outcome measures
| Measure |
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Other Risk Factors for UTI
Participants with UTI
|
2 days of catheterization
Interval 1.0 to 4.0
|
—
|
|
Other Risk Factors for UTI
participants without UTI
|
1 days of catheterization
Interval 1.0 to 3.0
|
—
|
SECONDARY outcome
Timeframe: 3 weeks following surgeryPopulation: Used entire study population to determine risk factors for UTI
We examined risk of UTI as related to postoperative catheter type
Outcome measures
| Measure |
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Other Risk Factors for UTI
participants without UTI
|
131 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with Foley
|
25 participants
|
—
|
|
Other Risk Factors for UTI
participants with UTI with self-catheterization
|
3 participants
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 weeks after surgeryPopulation: Examined urine cultures with susceptibility testing results for all participants who had positive urine culture results
We examined for macrobid resistance on urine culture results within 3 weeks of surgery
Outcome measures
| Measure |
Nitrofurantoin
n=9 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
|
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
|
|---|---|---|
|
Antibiotic Resistance to Macrobid
|
1 urine culture resistant to nitrofurantoi
|
—
|
Adverse Events
Nitrofurantoin
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place